Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Recombinant Vesicular Stomatitis Vaccine for Ebola · 1 trial · 1 indication
Antibody titers are examined by direct comparison of antibody titers in the blood. Serum-binding Ebola-specific antibody titers following rVSV∆G-ZEBOV-GP vaccination will be measured by Enzyme-Linked Immunosorbent Assay (ELISA).
| Arm | Type | Description |
|---|---|---|
| Recombinant Vesicular Stomatitis Vaccine for Ebola | EXPERIMENTAL | Healthy adults who are at no risk for exposure to Ebola Virus and are not prior recipients of an Ebola vaccine receive a single dose of recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP). |
| Recombinant Vesicular Stomatitis Vaccine for Ebola and Deuterium Labeled Water for 14 Days | EXPERIMENTAL | Healthy adults who are at no risk for exposure to Ebola Virus and are not prior recipients of an Ebola vaccine receive a single dose of recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) plus deuterium labeled water three times daily for 14 days from days 1-15. |
| Recombinant Vesicular Stomatitis Vaccine for Ebola and Deuterium Labeled Water for 28 Days | EXPERIMENTAL | Healthy adults who are at no risk for exposure to Ebola Virus and are not prior recipients of an Ebola vaccine receive a single dose of recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) plus deuterium labeled water three times daily for 28 days from days 57-85. |
| Name | Type | Description |
|---|---|---|
| Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) | BIOLOGICAL | The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm. |
| Deuterium Labeled Water | OTHER | An Emory Investigational Drug Service pharmacist will prepare sterile 50 ml aliquots of D2O with a tamper seal and stored at room temperature. Participants will be asked to drink a pre-measured volume of water three times a day and on days according to their assigned group schedule. |
Inclusion Criteria: * Signed informed consent for study. * For women of childbearing potential: willing to engage in effective methods of contraception starting at least 28 days prior to vaccination and during the study. * Willing to minimize blood and body fluid exposure to others (encourage absti...
Recombinant Vesicular Stomatitis Vaccine for Ebola is a vaccine being developed for Ebola Virus Disease. It is also known as rVSV∆G-ZEBOV-GP. It is an investigational product in Phase 2 clinical development, developed by Merck & Company, Inc. (ticker MRK).
Recombinant Vesicular Stomatitis Vaccine for Ebola is intended for Ebola Virus Disease. It is a vaccine candidate in the infectious disease therapeutic area. Its clinical development is at Phase 2, and it is being studied in healthy adult volunteers.
Recombinant Vesicular Stomatitis Vaccine for Ebola is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor associated with the vaccine's clinical development program for Ebola Virus Disease.
Recombinant Vesicular Stomatitis Vaccine for Ebola is in Phase 2 clinical development. It is an investigational vaccine and is not described as approved. The Phase 2 program consists of one trial, which is currently active.
Recombinant Vesicular Stomatitis Vaccine for Ebola is being studied in trial NCT06100913, titled Immunology of Ebola Vaccine. This Phase 2 trial is active but not recruiting, enrolls 30 participants, includes healthy volunteers aged 18 years and older of all sexes, and is conducted in the United States.
Yes. Recombinant Vesicular Stomatitis Vaccine for Ebola is also known as rVSV∆G-ZEBOV-GP. The two names refer to the same Ebola Virus Disease vaccine candidate developed by Merck & Company, Inc. (ticker MRK), currently in Phase 2 development.